Control of HCV replication with iMIRs, a novel anti-RNAi agent

Saori Itami, Yutaka Eguchi, Takayuki Mizutani, Eriko Aoki, Tadaaki Ohgi, Masahiko Kuroda, Takahiro Ochiya, Nobuyuki Kato, Hiroshi I. Suzuki, Norifumi Kawada, Yoshiki Murakami

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

MicroRNAs (miRNAs) serve important roles in regulating various physiological activities through RNA interference (RNAi). miR-122 is an important mediator of RNAi that is known to control hepatitis C virus (HCV) replication and is being investigated in clinical trials as a target for anti-HCV therapy. In this study, we developed novel oligonucleotides containing non-nucleotide residues, termed iMIRs, and tested their abilities to inhibit miR-122 function. We compared the inhibitory effects of iMIRs and locked nucleic acids (LNAs) on HCV replication in OR6 cells, which contained full-length HCV (genotype 1b) and a luciferase reporter gene. We found that RNA-type iMIRs with bulge-type, imperfect complementarity with respect to miR-122 were 10-fold more effective than LNAs in inhibiting HCV replication and functioned in a dose-dependent manner. Moreover, iMIR treatment of OR6 cells reduced HCV replication without inducing interferon responses or cellular toxicity. Based on these results, we suggest that iMIRs can inhibit HCV replication more effectively than LNAs and are therefore promising as novel antiviral agents.

Original languageEnglish
Article numbere219
JournalMolecular Therapy - Nucleic Acids
Volume4
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Virus Replication
RNA Interference
Hepacivirus
Luciferases
MicroRNAs
Reporter Genes
Oligonucleotides
Interferons
Antiviral Agents
Genotype
Clinical Trials
RNA
locked nucleic acid

Keywords

  • Anti-sense oligonucleotide
  • Hepatitis C virus
  • Interferon
  • Locked nucleic acid
  • MiRNA
  • RNA interference

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Itami, S., Eguchi, Y., Mizutani, T., Aoki, E., Ohgi, T., Kuroda, M., ... Murakami, Y. (2015). Control of HCV replication with iMIRs, a novel anti-RNAi agent. Molecular Therapy - Nucleic Acids, 4(1), [e219]. https://doi.org/10.1038/mtna.2014.71

Control of HCV replication with iMIRs, a novel anti-RNAi agent. / Itami, Saori; Eguchi, Yutaka; Mizutani, Takayuki; Aoki, Eriko; Ohgi, Tadaaki; Kuroda, Masahiko; Ochiya, Takahiro; Kato, Nobuyuki; Suzuki, Hiroshi I.; Kawada, Norifumi; Murakami, Yoshiki.

In: Molecular Therapy - Nucleic Acids, Vol. 4, No. 1, e219, 01.01.2015.

Research output: Contribution to journalArticle

Itami, S, Eguchi, Y, Mizutani, T, Aoki, E, Ohgi, T, Kuroda, M, Ochiya, T, Kato, N, Suzuki, HI, Kawada, N & Murakami, Y 2015, 'Control of HCV replication with iMIRs, a novel anti-RNAi agent', Molecular Therapy - Nucleic Acids, vol. 4, no. 1, e219. https://doi.org/10.1038/mtna.2014.71
Itami S, Eguchi Y, Mizutani T, Aoki E, Ohgi T, Kuroda M et al. Control of HCV replication with iMIRs, a novel anti-RNAi agent. Molecular Therapy - Nucleic Acids. 2015 Jan 1;4(1). e219. https://doi.org/10.1038/mtna.2014.71
Itami, Saori ; Eguchi, Yutaka ; Mizutani, Takayuki ; Aoki, Eriko ; Ohgi, Tadaaki ; Kuroda, Masahiko ; Ochiya, Takahiro ; Kato, Nobuyuki ; Suzuki, Hiroshi I. ; Kawada, Norifumi ; Murakami, Yoshiki. / Control of HCV replication with iMIRs, a novel anti-RNAi agent. In: Molecular Therapy - Nucleic Acids. 2015 ; Vol. 4, No. 1.
@article{82fcae0341ea42b1ba39184a35ae23fd,
title = "Control of HCV replication with iMIRs, a novel anti-RNAi agent",
abstract = "MicroRNAs (miRNAs) serve important roles in regulating various physiological activities through RNA interference (RNAi). miR-122 is an important mediator of RNAi that is known to control hepatitis C virus (HCV) replication and is being investigated in clinical trials as a target for anti-HCV therapy. In this study, we developed novel oligonucleotides containing non-nucleotide residues, termed iMIRs, and tested their abilities to inhibit miR-122 function. We compared the inhibitory effects of iMIRs and locked nucleic acids (LNAs) on HCV replication in OR6 cells, which contained full-length HCV (genotype 1b) and a luciferase reporter gene. We found that RNA-type iMIRs with bulge-type, imperfect complementarity with respect to miR-122 were 10-fold more effective than LNAs in inhibiting HCV replication and functioned in a dose-dependent manner. Moreover, iMIR treatment of OR6 cells reduced HCV replication without inducing interferon responses or cellular toxicity. Based on these results, we suggest that iMIRs can inhibit HCV replication more effectively than LNAs and are therefore promising as novel antiviral agents.",
keywords = "Anti-sense oligonucleotide, Hepatitis C virus, Interferon, Locked nucleic acid, MiRNA, RNA interference",
author = "Saori Itami and Yutaka Eguchi and Takayuki Mizutani and Eriko Aoki and Tadaaki Ohgi and Masahiko Kuroda and Takahiro Ochiya and Nobuyuki Kato and Suzuki, {Hiroshi I.} and Norifumi Kawada and Yoshiki Murakami",
year = "2015",
month = "1",
day = "1",
doi = "10.1038/mtna.2014.71",
language = "English",
volume = "4",
journal = "Molecular Therapy - Nucleic Acids",
issn = "2162-2531",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Control of HCV replication with iMIRs, a novel anti-RNAi agent

AU - Itami, Saori

AU - Eguchi, Yutaka

AU - Mizutani, Takayuki

AU - Aoki, Eriko

AU - Ohgi, Tadaaki

AU - Kuroda, Masahiko

AU - Ochiya, Takahiro

AU - Kato, Nobuyuki

AU - Suzuki, Hiroshi I.

AU - Kawada, Norifumi

AU - Murakami, Yoshiki

PY - 2015/1/1

Y1 - 2015/1/1

N2 - MicroRNAs (miRNAs) serve important roles in regulating various physiological activities through RNA interference (RNAi). miR-122 is an important mediator of RNAi that is known to control hepatitis C virus (HCV) replication and is being investigated in clinical trials as a target for anti-HCV therapy. In this study, we developed novel oligonucleotides containing non-nucleotide residues, termed iMIRs, and tested their abilities to inhibit miR-122 function. We compared the inhibitory effects of iMIRs and locked nucleic acids (LNAs) on HCV replication in OR6 cells, which contained full-length HCV (genotype 1b) and a luciferase reporter gene. We found that RNA-type iMIRs with bulge-type, imperfect complementarity with respect to miR-122 were 10-fold more effective than LNAs in inhibiting HCV replication and functioned in a dose-dependent manner. Moreover, iMIR treatment of OR6 cells reduced HCV replication without inducing interferon responses or cellular toxicity. Based on these results, we suggest that iMIRs can inhibit HCV replication more effectively than LNAs and are therefore promising as novel antiviral agents.

AB - MicroRNAs (miRNAs) serve important roles in regulating various physiological activities through RNA interference (RNAi). miR-122 is an important mediator of RNAi that is known to control hepatitis C virus (HCV) replication and is being investigated in clinical trials as a target for anti-HCV therapy. In this study, we developed novel oligonucleotides containing non-nucleotide residues, termed iMIRs, and tested their abilities to inhibit miR-122 function. We compared the inhibitory effects of iMIRs and locked nucleic acids (LNAs) on HCV replication in OR6 cells, which contained full-length HCV (genotype 1b) and a luciferase reporter gene. We found that RNA-type iMIRs with bulge-type, imperfect complementarity with respect to miR-122 were 10-fold more effective than LNAs in inhibiting HCV replication and functioned in a dose-dependent manner. Moreover, iMIR treatment of OR6 cells reduced HCV replication without inducing interferon responses or cellular toxicity. Based on these results, we suggest that iMIRs can inhibit HCV replication more effectively than LNAs and are therefore promising as novel antiviral agents.

KW - Anti-sense oligonucleotide

KW - Hepatitis C virus

KW - Interferon

KW - Locked nucleic acid

KW - MiRNA

KW - RNA interference

UR - http://www.scopus.com/inward/record.url?scp=84959369984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959369984&partnerID=8YFLogxK

U2 - 10.1038/mtna.2014.71

DO - 10.1038/mtna.2014.71

M3 - Article

AN - SCOPUS:84959369984

VL - 4

JO - Molecular Therapy - Nucleic Acids

JF - Molecular Therapy - Nucleic Acids

SN - 2162-2531

IS - 1

M1 - e219

ER -